SHANGHAI – For the second time this year, Eli Lilly and Co. entered a strategic collaboration agreement with a local Chinese company to co-develop a novel candidate for the China market, this time with Shanghai-based Wuxi Pharmatech (Cayman) Inc., the well-respected, multifunctional contract research organization (CRO) and contract manufacturer.